Cannabis Law Report
SEPTEMBER 13, 2021
(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. in the blood.
Cannabis Law Report
NOVEMBER 16, 2021
As cleared by the FDA, the primary endpoint of the Phase 2 double-blind, placebo-controlled clinical trial is to achieve a reduction in the circulating levels of tumor necrosis factor-alpha (TNF-?), The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
JANUARY 5, 2022
3 MyMD believes that there are no FDA-approved drugs for treating aging disorders and extending healthy lifespan in humans, a market expected to be at least $600 billion by 2025 according to a major investment bank. The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy.
Cannabis Law Report
MAY 19, 2019
billion dollars by 2025. Most of the proponents of the legalization of its use for both medical and recreational purposes have stated that its criminalization has not stopped its increasingly widespread use but instead, has helped deny people of its ‘wonder working powers’, as a drug, especially in treating chronic pain as earlier mentioned.
Cannabis Law Report
OCTOBER 17, 2019
Some of the potential health benefits associated with THC and CBD, with and without the high, respectively, include reducing chronic pain such as from migraines or cancer, alleviating anxiety, reducing inflammation, and helping treat conditions such as epilepsy, PTSD, and glaucoma. billion in 2025, according to Grandview Research.
Expert insights. Personalized for you.
52 
Let's personalize your content